Cell and Gene Therapy Biomanufacturing Market Overview
The global cell and gene therapy biomanufacturing market is estimated to reach $29.76 billion in 2031, reveals the premium market intelligence study. The study also highlights that the market is set to witness a CAGR of 10.31% during the forecast period 2022-2031.
The global cell and gene therapy biomanufacturing market is strongly driven by the rising incidence of target diseases such as orphan diseases, cancers, metabolic disorders, and autoimmune disorders, as well as the increasing approval of cell and gene therapies. The global cell and gene therapy biomanufacturing market has witnessed a steady growth in the number of new entrants and investments in cell and gene therapy, thereby driving a surge in demand for the consumables, equipment, and software solutions required in the manufacturing of these therapies. This trend is also expected to continue over the forecast period. Therefore, the impact of the aforementioned factors is expected to drive the global cell and gene therapy biomanufacturing market in the near future.
USP of the Report
• The major
USP of the Report
is the inclusion of software solutions along with the consumables and equipment required for the manufacturing of cell and gene therapy.
• The report provides numerical projections for the product type as well as end user in each geography.
• Additionally, the report also provides insights on COVID-19 and Russo-Ukrainian War on the global cell and gene therapy biomanufacturing market.
• Apart from this, the report focuses on key trends such as biomanufacturing 4.0 and assessment of the trends as well.
• The report also comprises key regulations, competitive landscape, key drivers and restraints, patent analysis, business model analysis, and company profiles with a detailed analysis of the strategies undertaken by the major company to strengthen its market presence.
Analyst Perspective
According to Akash Mhaskar, Lead Analyst of the report, “The global cell and gene therapy biomanufacturing market is strongly driven by the rising incidence of target diseases such as orphan diseases, cancers, metabolic disorders, and autoimmune disorders, among others, as well as the increasing approval of cell and gene therapies. The global cell and gene therapy biomanufacturing market has witnessed a steady growth in the number of new entrants and investments in cell and gene therapy, thereby driving a surge in demand for the consumables, equipment, and software solutions required in the manufacturing of these therapies. This trend is also expected to continue over the forecast period. Therefore, the impact of the aforementioned factors is expected to drive the global cell and gene therapy biomanufacturing market in the near future.”
Key Companies Operating in The Market
Key players in the global cell and gene therapy biomanufacturing market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global cell and gene therapy biomanufacturing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
The key players profiled in the report include Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Danaher Corporation, Endress+Hauser Group Services AG (Analytik Jena GmbH), General Electric Company (GE Healthcare), Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, PIERRE GUERIN, Sartorius AG (Sartorius Stedim Biotech S.A.), Thermo Fisher Scientific Inc., and WuXi AppTec
Key Questions Answered in the Report/h3>
• What are the three potential scenarios in which the global cell and gene therapy biomanufacturing market growth can unfold during 2022-2031?
• What are the impacts of COVID-19 and the Russo-Ukranian War on the global cell and gene therapy biomanufacturing market?
• What are the key trends influencing the global cell and gene therapy biomanufacturing market, and what is their potential for impacting the market?
• What is the patent landscape of the global cell and gene therapy biomanufacturing market like? Which year and country witnessed the maximum patent filing between
January 2020 and December 2022?
• What are the key regulations that impact the growth of the global cell and gene therapy biomanufacturing market?
• What are the key differences in equipment offered by key players?
• What are the key drivers, restraints, and opportunities for the global cell and gene therapy biomanufacturing market? What will be their impact on the market in short-, mid-, and long-term duration?
• Which product type is projected to be the fastest-growing segment during the forecast period 2022-2031?
• What is the key application for which consumables, equipment, and software solutions are utilized? Which application area is projected to be the fastest-growing
segment during the forecast period 2022-2031?
• Which segmentation holds the largest market share of the cell and gene therapy biomanufacturing market based on usage? Which one of those segments is expected
to be the fastest growing segment during the forecast period 2022-2031?
• Who are the major end users for the cell and gene therapy biomanufacturing market? Which end user held the largest share of the market in 2021?
• What are the anticipated regulatory milestones for 2023?
• What is the competitive landscape in the global cell and gene therapy biomanufacturing market?
• Who are the key players in the global cell and gene therapy biomanufacturing market, and what are their product offerings in the market?
Get the full report:
Cell and Gene Therapy Biomanufacturing Market Research Report
Leave a Reply